BRIEF—UK to fund Opdivo combo in lung cancer

The UK’s reimbursement agency, the National Institute for Health and Care Excellence (NICE), has recommended an Opdivo (nivolumab) and chemo combo in lung cancer.

The final guidance would unlock funding for the combination, for the neoadjuvant treatment of certain resectable non-small cell lung cancers (NSCLC) in adults.

Over 4,800 patients in England and Wales could be eligible to receive the treatment.

The therapy, marketed by US pharma major Bristol Myers Squibb, has been subjected to an expedited regulatory process through Project Orbis, a collaboration between global regulators aimed at bringing new treatments to patients faster.

The decision is backed by data from the Phase III CheckMate-816 trial.